Comparative Pharmacology
Head-to-head clinical analysis: AMBENYL versus BENZONATATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMBENYL versus BENZONATATE.
AMBENYL vs BENZONATATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AMBENYL is a combination product containing codeine (opioid agonist) and bromodiphenhydramine (antihistamine). Codeine binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception; bromodiphenhydramine antagonizes histamine H1 receptors, producing antitussive and sedative effects.
Benzonatate is a local anesthetic structurally related to tetracaine. It suppresses cough by anesthetizing stretch receptors in the respiratory tract, reducing the cough reflex.
Each 5 mL contains codeine phosphate 10 mg and diphenhydramine hydrochloride 12.5 mg. Adults: 10 mL (2 teaspoonfuls) orally every 4-6 hours as needed; maximum 40 mL per day.
100 mg to 200 mg orally three times daily as needed for cough.
None Documented
None Documented
Codeine: 2.5-3.5 h (terminal) with CYP2D6 poor metabolizers up to 6 h. Guaifenesin: 1-2 h.
Terminal elimination half-life is approximately 3–8 hours in adults; prolonged in hepatic impairment.
Renal: 60% unchanged codeine, 20% codeine-6-glucuronide; biliary/fecal: 20% as metabolites. Guaifenesin: renal 95% as unchanged drug and metabolites.
Primarily renal excretion of metabolites; unchanged benzonatate is negligible. Fecal elimination accounts for <5%. Biliary excretion is minimal.
Category C
Category A/B
Antitussive/Antihistamine Combination
Antitussive